Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS ® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients

Once-Weekly KYPROLIS at 70 mg/m2 Shows Superior Efficacy and Comparable Safety to Twice-Weekly KYPROLIS at 27 mg/m2 Positive Results From Pre-Specified Interim Analysis THOUSAND OAKS, Calif., Oct. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered once-weekly at the 70 mg/m2 dose with dexamethasone allowed relapsed and refractory multiple myeloma patients to live 3.6 months longer without their disease worsening than KYPROLIS administered twice-weekly at the 27 mg/m2 dose with dexamethasone. The overall safety profile of the once-weekly KYPROLIS regimen was comparable to that...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news